Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

By Kaj Blennow, Harald Hampel, Michael W. Weiner, Henrik Zetterberg. Nature Reviews Neurology, 2010

1,879 citations recorded by the source corpus.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/c7342bc120397c23c3f777e7cfeb0d76b76637e5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, methodology): “They are derived from neurogenetics [284–286], structural or functional or metabolic neuroimaging and neurophysiology [287,288], neurochemistry on biofluids [289–291], namely CSF [94,292,293] and blood (plasma/ serum) [218,232,236,237].”
What is normal in normal aging? Effects of Aging, Amyloid and Alzheimer’s Disease on the Cerebral Cortex and the Hippocampus (2014, background): “Both CSF levels of Ab1–42 and amyloid imaging with PIB PET reflect fibrillar Ab levels and amyloid plaque load in the brain (Blennow et al., 2010).”
CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts (2018, methodology): “In BioFINDER, CSF samples were collected per the Alzheimer’s Association Flow Chart for CSF biomarkers [32].”
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease (2017, background): “The main findings were that plasma NFL (1) correlated with CSF NFL independent of diagnosis, (2) was increased in the AD dementia group and in Aβ-positive patients with MCI, (3) had diagnostic accuracy for AD dementia in the same range as established CSF biomarkers, and (4) was associated with cogni”
Biomarkers for Alzheimer's disease: current status and prospects for the future (2018, background): “amyloid (1-42) assay was published (104).”
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, positive): “Because CSF P-tau and T-tau are highly correlated in AD and are equally correlated with tau PET [124], they do not seem to provide independent information in AD.”
A Practical Guide to Immunoassay Method Validation (2015, methodology): “Given that there exists a CRM, calculate the bias (bCRM) using formula (1) where the measured mean value (X) is calculated from five replicates and xref is the assigned reference value.”
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. (2012, methodology): “Therefore, patients with MCI with pathologic CSF biomarkers could be selected for clinical trials of new disease-modifying therapies.(5,6) Using this approach, fewer patients with MCI would be needed, and the potential beneficial effects of treatments would be easier to detect in such treatment tria”